A Prognostic Index for Advanced-stage Extranodal Natural Killer/T-cell Lymphoma: A Multicenter Study

Overview

Journal Ann Hematol

Specialty Hematology

Date 2025 Jan 8

PMID 39774927

Authors

Xiaojie Fang

Fenglan Zhou

Sheng Ye

Hongyu Zhang

Hongqiang Guo

Xinggui Chen

Chaoyong Liang

Xingxiang Pu

Yabing Cao

Quanguang Ren

Xiaoqian Li

Linzhu Zhai

He Huang

Huangming Hong

Affiliations

Soon will be listed here.

Abstract

Advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL) is a highly heterogeneous disease with very poor prognosis. All commonly utilized prognostic models incorporated both early-stage and advanced-stage patients in the modeling process. This study aim to design a prognostic model specifically for advanced-stage ENKTL, providing risk stratification in affected patients. We analyzed 291 patients with stage III/IV ENKTL receiving asparaginase-based chemotherapy from 8 institutions to develop a new prognostic model and validate it in an independent cohort consisted of 221 patients from 4 additional hospitals. The prognostic model included three independent variables based on a multivariate analysis for overall survival (OS): age, bone marrow invasiveness and visceral organ involvement. We identified three different risk groups: group 1, no adverse factors; group 2, one factor; and group 3, two or three factors, which were associated with 5-year OS rates of 66.0%, 32.3%, and 20.0%, respectively (P < 0.001). The prognostic index of natural killer lymphoma (PINK) and nomogram-revised risk index (NRI) were unsatisfactory for stratifying these patients. These results were validated and confirmed in an independent cohort. This newly proposed model can be used to guide risk-adapted treatment for advanced stage ENKTL.

References

Yoon S, Song Y, Kim S, Yoon D, Chen T, Koh Y . Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac. 2021; 10:100126. PMC: 8315366. DOI: 10.1016/j.lanwpc.2021.100126. View

Gao Y, He H, Li X, Zhang L, Xu W, Feng R . Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal Transduct Target Ther. 2024; 9(1):121. PMC: 11099117. DOI: 10.1038/s41392-024-01825-0. View

Zhang Y, Deng Y, Zou Q, Jing B, Cai P, Tian X . Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging. Cell Rep Med. 2024; 5(5):101551. PMC: 11148767. DOI: 10.1016/j.xcrm.2024.101551. View

Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M . Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012; 138(3):429-34. DOI: 10.1309/AJCP7YLTQPUSDQ5C. View

Kim T, Lee S, Jeon Y, Ryoo B, Cho G, Hong Y . Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008; 19(8):1477-1484. DOI: 10.1093/annonc/mdn147. View

Hong H, Huang H, Fang X, Wang Z, Ye S, Zhang H . A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Am J Hematol. 2019; 94(5):E122-E124. DOI: 10.1002/ajh.25426. View

Au W, Weisenburger D, Intragumtornchai T, Nakamura S, Kim W, Sng I . Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 113(17):3931-7. DOI: 10.1182/blood-2008-10-185256. View

Kwong Y, Kim W, Lim S, Kim S, Tang T, Tse E . SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120(15):2973-80. DOI: 10.1182/blood-2012-05-431460. View

Zhang Y, Ma S, Cai J, Yang Y, Jing H, Shuang Y . Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Am J Hematol. 2021; 96(11):1481-1490. PMC: 9291061. DOI: 10.1002/ajh.26335. View

10.

Wang X, Zhang L, Liu X, Li X, Li L, Fu X . Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial. JAMA Oncol. 2022; 8(7):1035-1041. PMC: 9204617. DOI: 10.1001/jamaoncol.2022.1968. View

11.

Tse E, Zhao W, Xiong J, Kwong Y . How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022; 15(1):74. PMC: 9164389. DOI: 10.1186/s13045-022-01293-5. View

12.

Lim S, Hong J, Lim S, Hong H, Arnoud J, Zhao W . Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017; 28(9):2199-2205. DOI: 10.1093/annonc/mdx316. View

13.

Tse E, Kwong Y . The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017; 10(1):85. PMC: 5391564. DOI: 10.1186/s13045-017-0452-9. View

14.

Chen S, Yang Y, Qi S, Wang Y, Hu C, He X . Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2020; 35(1):130-142. PMC: 7787971. DOI: 10.1038/s41375-020-0791-3. View

15.

Lin G, Xu C, Chen K, Huang H, Chen J, Song B . Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2019; 21(2):306-316. DOI: 10.1016/S1470-2045(19)30799-5. View

16.

Lee J, Suh C, Park Y, Ko Y, Bang S, Lee J . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2005; 24(4):612-8. DOI: 10.1200/JCO.2005.04.1384. View

17.

Kim S, Yoon D, Jaccard A, Chng W, Lim S, Hong H . A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3):389-400. DOI: 10.1016/S1470-2045(15)00533-1. View

18.

Allen P, Lechowicz M . Management of NK/T-Cell Lymphoma, Nasal Type. J Oncol Pract. 2019; 15(10):513-520. PMC: 6790879. DOI: 10.1200/JOP.18.00719. View

19.

Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H . Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2009; 21(5):1032-40. DOI: 10.1093/annonc/mdp418. View

20.

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View